NASDAQ:SHPG - Shire Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$179.20 0.00 (0.00 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$179.20
Today's Range$179.20 - $179.20
52-Week Range$123.73 - $182.47
Average Volume2.21 million shs
Market Capitalization$54.71 billion
P/E Ratio11.83
Dividend Yield0.19%
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SHPG



Sales & Book Value

Annual Sales$15.16 billion
Cash Flow$22.7123 per share
Book Value$119.43 per share


Net Income$4.27 billion


Market Cap$54.71 billion
Next Earnings DateN/A

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire announced a dividend on Thursday, August 2nd. Investors of record on Friday, September 7th will be given a dividend of $0.168 per share on Friday, October 19th. The ex-dividend date of this dividend is Thursday, September 6th. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire PLC (NASDAQ:SHPG) released its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. The firm's quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $3.63 earnings per share. View Shire's Earnings History.

What price target have analysts set for SHPG?

11 brokerages have issued 12 month target prices for Shire's shares. Their forecasts range from $195.00 to $222.00. On average, they expect Shire's share price to reach $201.60 in the next year. This suggests a possible upside of 12.5% from the stock's current price. View Analyst Price Targets for Shire.

What is the consensus analysts' recommendation for Shire?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:
  • 1. According to Zacks Investment Research, "Shire’s sales and earnings missed estimates in third-quarter 2018. The company launched Takhzyro, the first monoclonal antibody to prevent hereditary angioedema attacks, in the United States. It also gained approval for this innovative treatment in Canada and received a positive opinion from the Committee for Medicinal Products for Human Use, recommending marketing authorization in Europe. Shire continues to pay its debt while advancing its late-stage pipeline. Takeda’s proposed acquisition of Shire will close in first half of 2019, subject to additional regulatory approvals. The company completed the sale of its Oncology franchise to Servier S.A.S. in August 2018. In September, it acquired sanaplasma AG, a source plasma collection company that adds 14 new centers in the Czech Republic and Hungary to Shire’s European-based plasma collection network. Moreover, the company’s shares have outperformed the industry year to date." (11/15/2018)
  • 2. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018)

Has Shire been receiving favorable news coverage?

Media stories about SHPG stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Shire earned a news sentiment score of -1.1 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.

Who are some of Shire's key competitors?

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Cisco Systems (CSCO), Celgene (CELG), General Electric (GE), Intel (INTC), Pfizer (PFE), Walt Disney (DIS), Starbucks (SBUX), Johnson & Johnson (JNJ) and Amgen (AMGN).

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)

Who are Shire's major shareholders?

Shire's stock is owned by many different of retail and institutional investors. Top institutional investors include Third Point LLC (0.56%), Manikay Partners LLC (0.24%), Bank of America Corp DE (0.22%), LMR Partners LLP (0.17%), Baupost Group LLC MA (0.15%) and Gabelli Funds LLC (0.12%).

Which major investors are selling Shire stock?

SHPG stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, New South Capital Management Inc., Odey Asset Management Group Ltd, Samlyn Capital LLC, Tibra Equities Europe Ltd, NorthCoast Asset Management LLC and Delek Group Ltd..

Which major investors are buying Shire stock?

SHPG stock was bought by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, Quinn Opportunity Partners LLC, Fir Tree Capital Management LP, Oceanwood Capital Management Ltd., Gabelli Funds LLC, Third Point LLC, Paloma Partners Management Co and Harvest Management LLC.

How do I buy shares of Shire?

Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $179.20.

How big of a company is Shire?

Shire has a market capitalization of $54.71 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe.

What is Shire's official website?

The official website for Shire is

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]

MarketBeat Community Rating for Shire (NASDAQ SHPG)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,031 (Vote Outperform)
Underperform Votes:  563 (Vote Underperform)
Total Votes:  1,594
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by Staff

Featured Article: Why do corrections happen?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel